| 1090- | SANG, | Sanguinarine inhibits invasiveness and the MMP-9 and COX-2 expression in TPA-induced breast cancer cells by inducing HO-1 expression. |
| - | in-vitro, | BC, | MCF-7 |
| 1134- | SANG, | Sanguinarine inhibits epithelial–mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | HCC, | Hep3B | - | in-vitro, | HCC, | HUH7 |
| 3853- | SAS, | Sulfur-containing therapeutics in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 5139- | SAS, | Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis |
| - | in-vitro, | OS, | MG63 | - | in-vitro, | OS, | U2OS |
| 5045- | SAS, | Sulfasalazine, a potent cystine-glutamate transporter inhibitor, enhances osteogenic differentiation of canine adipose-derived stem cells |
| - | in-vivo, | Var, | NA |
| 5044- | SAS, | xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma |
| - | in-vitro, | Var, | NA |
| 5043- | SAS, | Chronic Sulfasalazine Treatment in Mice Induces System xc− - Independent Adverse Effects |
| - | in-vivo, | Nor, | NA |
| 5042- | SAS, | xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling |
| - | Review, | Var, | NA |
| 5041- | SAS, | Cisplatin, | Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism |
| - | in-vitro, | CRC, | NA |
| 5040- | SAS, | Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MCF-7 |
| 5141- | SAS, | Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B |
| - | in-vitro, | CRC, | SW-620 |
| 5140- | SAS, | Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β |
| - | in-vitro, | AML, | Jurkat | - | in-vitro, | CRC, | SW-620 |
| 5138- | SAS, | Rad, | Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion |
| - | vitro+vivo, | GBM, | NA |
| 5039- | SAS, | Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer |
| - | vitro+vivo, | BC, | NA |
| 5038- | SAS, | Rad, | Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma |
| - | in-vivo, | Melanoma, | B16-F10 |
| 5037- | SAS, | Inhibition of xCT by sulfasalazine alleviates the depression-like behavior of adult male mice subjected to maternal separation stress |
| - | in-vivo, | Nor, | NA |
| 5036- | SAS, | Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 5035- | SAS, | Sulfasalazine, a potent suppressor of gastric cancer proliferation and metastasis by inhibition of xCT: Conventional drug in new use |
| - | Human, | GC, | NA | - | in-vitro, | GC, | NCI-N87 | - | in-vitro, | GC, | SGC-7901 |
| 1388- | Sco, | Scoulerine promotes cell viability reduction and apoptosis by activating ROS-dependent endoplasmic reticulum stress in colorectal cancer cells |
| - | in-vitro, | CRC, | NA |
| 1403- | SDT, | BBR, | From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | LLC1 |
| 2549- | SDT, | Landscape of Cellular Bioeffects Triggered by Ultrasound-Induced Sonoporation |
| - | Review, | Var, | NA |
| 2536- | SDT, | Sonodynamic Therapy: Rapid Progress and New Opportunities for Non-Invasive Tumor Cell Killing with Sound |
| - | Review, | Var, | NA |
| 2551- | SDT, | Sonoporation: Past, Present, and Future |
| - | Review, | Var, | NA |
| 2550- | SDT, | Intracellular Delivery and Calcium Transients Generated in Sonoporation Facilitated by Microbubbles |
| - | in-vitro, | Nor, | NA |
| 2537- | SDT, | Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers |
| - | Review, | Var, | NA |
| 2548- | SDT, | Sonoporation, a Novel Frontier for Cancer Treatment: A Review of the Literature |
| - | Review, | Var, | NA |
| 2141- | Se, | Selenium and cancer risk: Wide-angled Mendelian randomization analysis |
| - | Review, | NA, | NA |
| 2140- | Se, | Selenium Exposure and Cancer Risk: an Updated Meta-analysis and Meta-regression |
| - | Review, | Var, | NA |
| 2142- | Se, | A U-shaped association between selenium intake and cancer risk |
| - | Review, | NA, | NA |
| 1696- | Se, | Selenium dietary intake and survival among CRC patients |
| - | Human, | CRC, | NA |
| 1695- | Se, | Serum Selenium Concentration as a Potential Diagnostic Marker for Early-Stage Colorectal Cancer: A Comparative Study |
| - | Trial, | CRC, | NA |
| 1689- | Se, | Selenium and breast cancer - An update of clinical and epidemiological data |
| - | Analysis, | BC, | NA |
| 1690- | Se, | Selenium and cancer: a story that should not be forgotten-insights from genomics |
| - | Review, | Var, | NA |
| 1691- | Se, | The influence of selenium and selenoprotein gene variants on colorectal cancer risk |
| - | Analysis, | CRC, | NA |
| 1692- | Se, | Association of Selenoprotein and Selenium Pathway Genotypes with Risk of Colorectal Cancer and Interaction with Selenium Status |
| - | Analysis, | CRC, | NA |
| 1693- | Se, | Prediagnostic selenium status, selenoprotein gene variants and association with breast cancer risk in a European cohort study |
| - | Analysis, | BC, | NA |
| 1694- | Se, | Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer |
| - | Analysis, | CRC, | NA |
| 1705- | Se, | Serum Selenium Level and 10-Year Survival after Melanoma |
| - | Study, | Melanoma, | NA |
| 1704- | Se, | Prospective study of toenail selenium levels and cancer among women |
| - | Study, | Var, | NA |
| 1703- | Se, | An Assessment of Serum Selenium Concentration in Women with Endometrial Cancer |
| - | Study, | EC, | NA |
| 1702- | Se, | Supplemental Selenium May Decrease Ovarian Cancer Risk in African-American Women |
| - | Human, | Ovarian, | NA |
| 1701- | Se, | An Assessment of Serum Selenium Concentration in Women with Ovarian Cancer |
| - | Human, | Ovarian, | NA |
| 1700- | Se, | Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers |
| - | Review, | Var, | NA |
| 1699- | Se, | Vegetarianism and colorectal cancer risk in a low-selenium environment: effect modification by selenium status? A possible factor contributing to the null results in British vegetarians |
| - | Analysis, | CRC, | NA |
| 1698- | Se, | Association between Dietary Zinc and Selenium Intake, Oxidative Stress-Related Gene Polymorphism, and Colorectal Cancer Risk in Chinese Population - A Case-Control Study |
| - | Human, | CRC, | NA |
| 4214- | Se, | Selenium ameliorates cognitive impairment through activating BDNF/TrkB pathway |
| - | in-vivo, | NA, | NA |
| 4751- | Se, | Chemo, | Selenium Protects Against Toxicity Induced by Anticancer Drugs and Augments Antitumor Activity: A Highly Selective, New, and Novel Approach for the Treatment of Solid Tumors |
| - | in-vivo, | Var, | NA |
| 4755- | Se, | Chemo, | Selenium Prevention of Alopecia, Bladder and Kidney Toxicity Induced by Chemotherapeutic Agents |
| - | in-vitro, | Var, | NA |
| 4754- | Se, | Chemo, | The effect of selenium yeast in the prevention of adverse reactions related to platinum-based combination therapy in patients with malignant tumors |
| - | Trial, | Var, | NA |
| 4757- | Se, | Chemo, | The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients |
| - | Trial, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid